KLIFO, a leading integrated drug development and clinical supply services provider with over 30 years of expertise, has received official manufacturing and importation authorisation from the Danish Medicines Agency for its new 65,000 sq ft Abildager facility in Copenhagen.

The approval marks a key milestone in KLIFO’s growth strategy and reinforces its commitment to delivering innovative, flexible, and sustainable clinical supply trial solutions for pharmaceutical and biotechnology companies worldwide.

The purpose-built facility significantly expands KLIFO’s capacity to support everything from small-scale studies to large global Phase III and post-marketing trials. It offers comprehensive temperature-controlled environments ranging from controlled room temperature to -80°C, and features low-light capabilities to handle light-sensitive products efficiently.

“Approval of our new facility represents a major step forward for KLIFO, and the site has already attracted strong interest from Nordic and international clients, further strengthening Copenhagen’s position as a European life science hub,” said René Pedersen, CEO, KLIFO.

With its advanced infrastructure, experienced team, and compliance with global quality standards, KLIFO aims to accelerate project setup, reduce turnaround times, and minimise supply chain disruptions across global clinical trials.